Targeted therapy before and after surgery for BRAF-mutant anaplastic thyroid cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of thyroid cancer called anaplastic (ATC) that has a BRAF V600E or V600K gene change.
- The cancer has not spread to other parts of your body (no distant metastases).
- Your airway is clear, or you have a tube or stent to keep it open, and you can swallow pills.
- You have not had any prior chemotherapy, immunotherapy, or radiation for this cancer.
- You are in good overall health (able to do daily activities) and your blood test results meet specific safety limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, pembrolizumab and lenvatinib, for people with a rare and aggressive thyroid cancer that cannot be removed by surgery. The goal is to see if this treatment can shrink the tumor or slow its growth.
This trial tests a combination of two medications—zanzalintinib (a targeted drug that may stop cancer cells from growing) and cemiplimab (an immunotherapy that helps your immune system fight cancer)—for people with anaplastic thyroid cancer, a rare and aggressive type. The goal is to see if this combo helps shrink or control the cancer.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
This trial compares a targeted therapy pill combination (dabrafenib and trametinib) with cabozantinib or chemotherapy for people with a specific type of advanced thyroid cancer (differentiated thyroid cancer) that has a BRAF V600E mutation. It aims to find which treatment works better after previous treatments have stopped working.
Hear when a new Anaplastic Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.